\uff5e Bristol Myers Squibb\u793e\u306fCelgene\u793e\u3068\u306e\u5408\u4f75\u306b\u3088\u308a\u3001\u81e8\u5e8a\u8a66\u9a13\u7ba1\u7406\u30b7\u30b9\u30c6\u30e0\u3092<\/p>\n
\u5358\u4e00\u30b7\u30b9\u30c6\u30e0\u306b\u7d71\u5408\u3055\u305b\u3001Vault CTMS\u3092\u8a18\u9332\u7684\u306a\u30b9\u30d4\u30fc\u30c9\u3067\u672c\u683c\u7a3c\u50cd<\/p>\n
\u30b7\u30b9\u30c6\u30e0\u306e\u6700\u65b0\u5316\u3067\u81e8\u5e8a\u8a66\u9a13\u7ba1\u7406\u3092\u30b9\u30ea\u30e0\u5316\u3057\u3001\u8fc5\u901f\u306b\u60a3\u8005\u69d8\u3078\u533b\u85ac\u54c1\u3092\u63d0\u4f9b\u3000\uff5e<\/p>\n
<\/p>\n
2022\u5e744\u670827\u65e5<\/p>\n
Veeva Japan\u682a\u5f0f\u4f1a\u793e<\/p>\n
Veeva Systems\u3010NYSE:VEEV\u3011\uff08\u672c\u793e : \u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5dde\u30d7\u30ec\u30b6\u30f3\u30c8\u30f3\u3001\u65e5\u672c\u6cd5\u4eba \u672c\u793e : \u6771\u4eac\u90fd\u6e0b\u8c37\u533a\u3001\u65e5\u672c\u6cd5\u4eba\u4ee3\u8868\u53d6\u7de0\u5f79 : Sebastian Bather\u3001\u4ee5\u4e0b Veeva\uff09\u306f\u3001Bristol Myers Squibb\u793e\u304c\u30a8\u30f3\u30c9\u30c4\u30fc\u30a8\u30f3\u30c9\u306a\u81e8\u5e8a\u8a66\u9a13\u7ba1\u7406\u3092\u63a8\u9032\u3059\u308b\u305f\u3081\u306bVeeva Vault CTMS<\/a><\/strong>\u3092\u30b0\u30ed\u30fc\u30d0\u30eb\u5168\u793e\u306b\u5c0e\u5165\u3057\u305f\u3068\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u65b0\u305f\u306b\u5c0e\u5165\u3055\u308c\u305fCTMS\u306f\u3001Celgene\u793e\u7531\u6765\u306eCTMS\u3068Bristol Myers Squibb\u793e\u7531\u6765\u306eCTMS\u306b\u4ee3\u308f\u308b\u30b7\u30b9\u30c6\u30e0\u3067\u3001Veeva\u306eeTMF\u304a\u3088\u3073Study Startup\u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\u3068\u7dca\u5bc6\u306b\u7d71\u5408\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u5c0e\u5165\u671f\u9593\u306f\u7dcf\u8a08\u306720\u30ab\u6708\u672a\u6e80\u3067\u3057\u305f\u3002 (\u672c\u30ea\u30ea\u30fc\u30b9\u306f\u3001Veeva\u7c73\u56fd\u672c\u793e\u304c\u767a\u8868\u3057\u305f\u5831\u9053\u8cc7\u6599\u306e\u6284\u8a33\u3067\u3059\u3002\u539f\u6587\u306f\u3053\u3061\u3089<\/a><\/strong>\u304b\u3089\u304a\u8aad\u307f\u3044\u305f\u3060\u3051\u307e\u3059\u3002)<\/p>\n <\/p>\n Bristol Myers Squibb\u793e\u306f\u3001Veeva\u304c\u63d0\u4f9b\u3059\u308b\u696d\u754c\u6700\u5148\u7aef\u306e\u81e8\u5e8a\u8a66\u9a13\u7ba1\u7406\u304a\u3088\u3073\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u3092\u5168\u793e\u306b\u5c55\u958b\u3057\u3001\u81e8\u5e8a\u8a66\u9a13\u306e\u8fc5\u901f\u5316\u3068\u52b9\u7387\u5316\u3092\u76ee\u7684\u3068\u3057\u305f\u30a2\u30b8\u30e3\u30a4\u30eb\u3067\u30b7\u30f3\u30d7\u30eb\u306a\u7d71\u5408\u5316\u3055\u308c\u305f\u81e8\u5e8a\u8a66\u9a13\u30d7\u30ed\u30bb\u30b9\u3092\u78ba\u7acb\u3057\u307e\u3057\u305f\u3002<\/p>\n Bristol Myers Squibb\u793e\u306e\u30c7\u30b8\u30bf\u30eb\u304a\u3088\u3073\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u306e\u6700\u9ad8\u8cac\u4efb\u8005\u3067\u3042\u308bGreg Meyers\u6c0f\u306f\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300cVeeva\u793e\u3068\u306eR&D\u5168\u822c\u306b\u308f\u305f\u308b\u9577\u5e74\u306e\u30d1\u30fc\u30c8\u30ca\u30fc\u30b7\u30c3\u30d7\u3092\u3055\u3089\u306b\u62e1\u5927\u3055\u305b\u308b\u3053\u3068\u306b\u306a\u308a\u3001\u5927\u3044\u306b\u671f\u5f85\u3057\u3066\u3044\u307e\u3059\u3002\u9867\u5ba2\u306e\u6210\u529f\u3068\u88fd\u54c1\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u306b\u5bfe\u3059\u308bVeeva\u306e\u7d99\u7d9a\u7684\u306a\u53d6\u7d44\u307f\u306f\u3001\u533b\u85ac\u54c1\u306e\u958b\u767a\u3068\u60a3\u8005\u69d8\u3078\u306e\u63d0\u4f9b\u3092\u30b0\u30ed\u30fc\u30d0\u30eb\u306b\u52a0\u901f\u3067\u304d\u308b\u3088\u3046\u652f\u63f4\u3057\u3066\u304f\u308c\u3066\u3044\u307e\u3059\u3002\u300d<\/p>\n Veeva\u306eCEO\u3001Peter Gassner\u306f\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300cBristol Myers Squibb\u793e\u306f\u5f0a\u793e\u306e\u30d1\u30fc\u30c8\u30ca\u30fc\u306e\u4e2d\u3067\u3082\u6307\u6298\u308a\u306e\u30a2\u30b8\u30e3\u30a4\u30eb\u3067\u5148\u9032\u7684\u306a\u4f01\u696d\u3067\u3059\u3002Celgene\u793e\u3068\u306e\u5408\u4f75\u306f\u88fd\u85ac\u696d\u754c\u53f2\u4e0a\u3067\u6700\u5927\u306eIT\u7d71\u5408\u30d7\u30ed\u30b8\u30a7\u30af\u30c8\u3067\u3057\u305f\u304c\u3001\u5358\u4e00\u306eCTMS\u306e\u5c0e\u5165\u309220\u30ab\u6708\u3067\u5b8c\u4e86\u3057\u305f\u3053\u3068\u306f\u307e\u3055\u306b\u753b\u671f\u7684\u3067\u3059\u3002\u3053\u306e\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u3092\u5354\u529b\u3057\u3066\u9054\u6210\u3067\u304d\u305f\u3053\u3068\u3092\u5927\u5909\u3046\u308c\u3057\u304f\u601d\u3044\u307e\u3059\u3002\u300d<\/p>\n Veeva Vault CTMS\u62c5\u5f53\u30f4\u30a1\u30a4\u30b9\u30d7\u30ec\u30b8\u30c7\u30f3\u30c8\u306eHenry Galio\u306f\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300cVeeva Vault CTMS\u306f\u5148\u9032\u7684\u306a\u6a5f\u80fd\u306b\u3088\u308a\u3001\u898f\u6a21\u306e\u5927\u5c0f\u3092\u554f\u308f\u305a\u81e8\u5e8a\u8a66\u9a13\u306e\u5b9f\u65bd\u3092\u7c21\u7d20\u5316\u3057\u307e\u3059\u3002\u4eca\u56de\u306e\u304d\u308f\u3081\u3066\u91cd\u8981\u3067\u8907\u96d1\u306aCTMS\u5c0e\u5165\u306b\u3042\u305f\u308a\u3001\u3059\u3070\u3089\u3057\u3044\u30d1\u30fc\u30c8\u30ca\u30fc\u30b7\u30c3\u30d7\u3092\u767a\u63ee\u3057\u3066\u304f\u3060\u3055\u3063\u305fBristol Myers Squibb\u793e\u306e\u30c1\u30fc\u30e0\u306b\u611f\u8b1d\u7533\u3057\u4e0a\u3052\u307e\u3059\u3002\u300d<\/p>\n <\/p>\n \u3010<\/strong>Veeva Systems<\/strong>\u793e\u306b\u3064\u3044\u3066\u3011<\/strong> \u3010Forward-looking Statements<\/strong>\u3011<\/strong> Bristol Myers Squibb\u793e\u306fCelgene\u793e\u3068\u306e\u5408\u4f75\u306b\u3088\u308a\u3001\u81e8\u5e8a\u8a66\u9a13\u7ba1\u7406\u30b7\u30b9\u30c6\u30e0\u3092\u5358\u4e00\u30b7\u30b9\u30c6\u30e0\u306b\u7d71\u5408\u3055\u305b\u3001Vault CTMS\u3092\u8a18\u9332\u7684\u306a\u30b9\u30d4\u30fc\u30c9\u3067\u672c\u683c\u7a3c\u50cd<\/p>\n","protected":false},"author":131,"featured_media":47089,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[322,341],"tags":[],"class_list":["post-47082","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","category-case-study"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/47082"}],"collection":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/comments?post=47082"}],"version-history":[{"count":6,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/47082\/revisions"}],"predecessor-version":[{"id":47154,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/47082\/revisions\/47154"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/media\/47089"}],"wp:attachment":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/media?parent=47082"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/categories?post=47082"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/tags?post=47082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nVeeva Systems\u793e\u306f\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u5411\u3051\u306b\u30af\u30e9\u30a6\u30c9\u30d9\u30fc\u30b9\u306e\u30bd\u30d5\u30c8\u30a6\u30a7\u30a2\u3092\u63d0\u4f9b\u3059\u308b\u30ea\u30fc\u30c7\u30a3\u30f3\u30b0\u30ab\u30f3\u30d1\u30cb\u30fc\u3067\u3059\u3002\u4e16\u754c\u6700\u5927\u898f\u6a21\u306e\u88fd\u85ac\u4f1a\u793e\u304b\u3089\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u5206\u91ce\u306e\u65b0\u8208\u4f01\u696d\u307e\u30671,100\u793e\u3092\u8d85\u3048\u308b\u9867\u5ba2\u306b\u3001\u6280\u8853\u9769\u65b0\u3078\u306e\u53d6\u308a\u7d44\u307f\u3084\u5353\u8d8a\u3057\u305f\u88fd\u54c1\u529b\u306b\u3088\u3063\u3066\u3001\u304a\u5ba2\u69d8\u306e\u6210\u529f\u306b\u30b3\u30df\u30c3\u30c8\u3059\u308b\u69d8\u3005\u306a\u30b5\u30fc\u30d3\u30b9\u3092\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002\u30d1\u30d6\u30ea\u30c3\u30af\u30fb\u30d9\u30cd\u30d5\u30a3\u30c3\u30c8\u30fb\u30b3\u30fc\u30dd\u30ec\u30fc\u30b7\u30e7\u30f3\u4f01\u696d\u3068\u3057\u3066Veeva\u306f\u3001\u9867\u5ba2\u3084\u5f93\u696d\u54e1\u3001\u63d0\u643a\u4f01\u696d\u3001\u682a\u4e3b\u3001\u30b5\u30fc\u30d3\u30b9\u63d0\u4f9b\u696d\u754c\u3092\u542b\u3080\u3059\u3079\u3066\u306e\u30b9\u30c6\u30fc\u30af\u30db\u30eb\u30c0\u30fc\u306e\u5229\u76ca\u30d0\u30e9\u30f3\u30b9\u3092\u4fdd\u3064\u3053\u3068\u306b\u30b3\u30df\u30c3\u30c8\u3057\u307e\u3059\u3002\u8a73\u3057\u304f\u306f\u3001veeva.com\/jp<\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/p>\n
\nThis release contains forward-looking statements regarding Veeva\u2019s products and services and the expected results or benefits from use of our products and services. Such statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the period ended January 31, 2022, which you can find here<\/a> (a summary of risks which may impact our business can be found on pages 13 and 14), and in our subsequent SEC filings, which you can access at sec.gov<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"